Account
UPPER MERION, Pa.--Drug maker GlaxoSmithKline PLC (GSK, GSK.LN) is keeping regulators busy with six new drug applications under review but 2013 also is shaping up as a pivotal year for the next wave of medicines in Glaxo's research-and-development pipeline.Results could emerge later this year from Phase 3, or late-stage, patient studies of a cancer therapeutic vaccine and a drug for cardiovascular disease, shedding light on whether they are safe and effective enough for regulatory submission. The drugs have sizeable sales potential if studies are successful and they gain regulatory clearance, analysts have said.Glaxo's chairman of R&D, Moncef Slaoui, described this next wave of therapies as "highly innovative" and potentially the first of their kind, whereas most of the half-dozen Glaxo drugs currently awaiting regulatory decisions won't be first-in-class.In an interview at a Glaxo R&D site outside Philadelphia, Dr. Slaoui said most of the drugs currently in regulatory review--includin...
After largely rising in the previous period, short interest in biotech and emerging pharmaceutical companies was mixed in the final two weeks of September. Shares so...
These are the stocks that are up on above-average volume today:Aetna (NYSE:AET) is up on high volume today, trading with volume of 9.1 million, or 3.2 times its aver...
During trading today, the Health Care sector (XLV) showed little change while the S&P 500 fell 0.9%.The ETF, as a as a proxy for sector performance, was down today, ...
These are stocks that are up on high volume today:Trading with a volume of 9.9 million, or two times its average daily volume, Baidu (NASDAQ:BIDU) is up on high volu...
These stocks are up on high volume today:Quest Software (NASDAQ:QSFT) is up on high volume today, trading with volume of 13.5 million, or 13 times its average daily ...
During trading today, both the Health Care sector (XLV) and the S&P500 showed little movement.AmerisourceBergen (NYSE:ABC) declined 1.5% to close at $36.45, moving b...
Here are stocks that are up on high volume:Trading with a volume of 38.2 million, or 2.4 times its average daily volume, Arena Pharmaceuticals (NASDAQ:ARNA) is up on...
During trading today, both the Health Care sector (XLV) and the S&P500 showed little movement.As a proxy for the sector, the ETF tracked closer to the overall market...
During trading today, the Health Care sector (XLV) showed little change while the S&P 500 fell 0.6%.The ETF is up 0.7% from its 50-day moving average and 5.4% from i...
With the United States spending more on healthcare than any other country - $2.5 trillion, or just over $8,000 per capita, in 2009 - the question has long been, is i...
Shares of Dendreon Corp. plunged 18% to $12.12 on Monday after it issued a weaker-than-expected quarterly sales report for its prostate cancer therapy Provenge. Dend...
Dendreon Corp. (DNDN) replaced its chief executive who steered the company on a difficult path toward regulatory approval of a new prostate-cancer therapy, only to f...
The short interest in biotech and emerging pharmaceutical companies was mixed again in the first two weeks of December. The number of shares sold short in Amgen (NAS...
The short interest in biotech and emerging pharmaceutical companies was mixed again in the final two weeks of November. Shares sold short in Alexion Pharmaceuticals ...
Dozens of U.S. companies postponed releasing quarterly results after superstorm Sandy hit the U.S. east coast, disrupting power supplies and transportation and flood...
Dozens of U.S. companies postponed releasing quarterly results as Sandy, one of the biggest storms to hit the United States, pounded the east coast, flooding large p...
A number of U.S. companies disclosed plans to postpone their quarterly reports because of the pending arrival of Hurricane Sandy on the East Coast, a move that comes...
Dozens of U.S. companies postponed releasing quarterly results as Hurricane Sandy headed towards the U.S. East Coast on Monday.Forecasters said the 1,000-mile-wide (...
The short interest in biotech and emerging pharmaceutical companies was mixed in the first two weeks of October. Shares sold short in Alexion Pharmaceuticals (NASDAQ...
